CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 23, 2018--
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host
its second quarter 2018 investor update conference call and webcast at
8:30 a.m. Eastern Time on Monday, August 6, 2018. Individuals interested
in participating in the call should dial (877) 643-7155 (U.S. and
Canada) or (914) 495-8552 (international) using conference ID number
5795089. To access the webcast, please visit the Investors section of
Ironwood’s website at www.ironwoodpharma.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
The call will be available for replay via telephone starting August 6,
2018 at approximately 11:30 a.m. Eastern Time, running through 11:30
a.m. Eastern Time on August 13, 2018. To listen to the replay, dial
(855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using
conference ID number 5795089. The archived webcast will be available on
Ironwood’s website for 14 days beginning approximately one hour after
the call has completed.
About Ironwood Pharmaceuticals
Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company
focused on creating medicines that make a difference for patients,
building value for our fellow shareholders, and empowering our
passionate team. We are commercializing two innovative primary care
products: linaclotide, the U.S. branded prescription market leader for
adults with irritable bowel syndrome with constipation (IBS-C) or
chronic idiopathic constipation (CIC), and lesinurad, which is approved
to be taken with a xanthine oxidase inhibitor (XOI), or as a fixed-dose
combination with allopurinol, for the treatment of hyperuricemia
associated with gout. We are also advancing a pipeline of innovative
product candidates in areas of significant unmet need, including
persistent gastroesophageal reflux disease, diabetic nephropathy, heart
failure with preserved ejection fraction, achalasia and sickle cell
disease. Ironwood was founded in 1998 and is headquartered in Cambridge,
Mass. For more information, please visit www.ironwoodpharma.com
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180723005706/en/
Source: Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Meredith Kaya, 617-374-5082
President, Investor Relations and Corporate Communications